Beijing Immunochina Raises $15 Million for CAR-T Portfolio

Beijing Immunochina Pharma  raised $15 million in C+ round of financing to support its portfolio of 12 CAR-T candidates.  Established in 2015, Beijing Immunochina has developed a serum-free production process and large-scale gene vector production platforms to improve the safety and efficacy of CAR-T products. It has started clinical trials for one CAR-T candidate, IM19, that it is co-developing with China 's Simcere Pharma for leukemia and non-Hodgkin's lymphoma. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.